Table 1.

Patient baseline characteristics

Characteristic	N = 40
Median age (range), y	69 (52-83)
Sex, male/female	35/5
WHO PS score, n (%)
0	14 (35.0)
1	21 (52.5)
2	4 (10.0)
Missing	1 (2.5)
MIPI score, n (%)
Low (<5.7)	10 (25)
Intermediate (5.7-6.2)	16 (40)
High (>6.2)	14 (35)
Risk factors, n (%)
Age >60 y	35 (88)
WHO PS ≥2	4 (10)
LDH >ULN	18 (45)
WBC >ULN	6 (15)
Bulky disease (>5 cm)	24 (60)
Treatment history
Median number of prior therapies (range)	4 (1-14)
≥6 regimens, n (%)	13 (32)
Prior therapy type, n (%)
Rituximab	40 (100)
Alkylating agent	39 (98)
Anthracycline	35 (88)
Bortezomib	24 (60)
Bendamustine	12 (40)
Autologous stem cell transplantation	9 (22)
Purine analog	9 (23)
Lenalidomide	8 (20)
Refractory to last regimen, n (%)	17 (43)

LDH, lactic dehydrogenase; PS, performance status; ULN, upper limit of normal; WBC, white blood cell count; WHO, World Health Organization.